

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJLK1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	4	APR 07	STN is raising the limits on saved answers
NEWS	5	APR 24	CA/CAPLUS now has more comprehensive patent assignee information
NEWS	6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	7	APR 28	CAS patent authority coverage expanded
NEWS	8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS	10	MAY 08	STN Express, Version 8.4, now available
NEWS	11	MAY 11	STN on the Web enhanced
NEWS	12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS	13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS	14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS	15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS	16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:03:05 ON 05 JUN 2009

=> FILE REG		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 20:03:41 ON 05 JUN 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JUN 2009 HIGHEST RN 1152369-03-3
 DICTIONARY FILE UPDATES: 4 JUN 2009 HIGHEST RN 1152369-03-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> E ectoine/CN

E1	1	ECTOIN/CN
E2	1	ECTOIN SYNTHASE/CN
E3	1 -->	ECTOINE/CN
E4	1	ECTOINE HYDROXYLASE (BORDETTELLA AVIUM STRAIN 197N GENE THPD) /CN
E5	1	ECTOINE HYDROXYLASE (CHROMOHALOBACTER SALEXIGENS STRAIN DSM 3043 GENE ECTD)/CN
E6	1	ECTOINE HYDROXYLASE (ECTD) (BRADYRHIZOBIUM STRAIN BTAI1)/CN
E7	1	ECTOINE HYDROXYLASE (ECTD) (BRADYRHIZOBIUM STRAIN ORS278)/CN
E8	1	ECTOINE HYDROXYLASE (HYPHOMONAS NEPTUNIUM STRAIN ATCC 15444) /CN
E9	1	ECTOINE HYDROXYLASE (NOCARDIA FARCIINICA STRAIN IFM 10152 GEN E ECTD)/CN
E10	1	ECTOINE HYDROXYLASE (SACCHAROPOLYSPORA ERYTHRAEA STRAIN NRRL 2338 GENE ECTD)/CN
E11	1	ECTOINE SYNTHASE/CN
E12	1	ECTOINE SYNTHASE (ALCANIVORAX BORKUMENSIS STRAIN SK2 GENE EC TC)/CN

=> S e3


L1 1 ECTOINE/CN

=> D L1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 96702-03-3 REGISTRY
 ED Entered STN: 09 Jun 1985
 CN 4-Pyrimidinecarboxylic acid, 3,4,5,6-tetrahydro-2-methyl-, (4S)- (CA
 INDEX NAME)
 OTHER CA INDEX NAMES:

CN 4-Pyrimidinecarboxylic acid, 1,4,5,6-tetrahydro-2-methyl-, (4S)- (9CI)
 CN 4-Pyrimidinecarboxylic acid, 1,4,5,6-tetrahydro-2-methyl-, (S)-
 OTHER NAMES:
 CN Ectoin
 CN Ectoïne
 CN NSC 614616
 CN Pyrostatin B
 CN Pyrostatine B
 CN RonaCare
 FS STEREOSEARCH
 DR 162763-51-1, 134522-10-4
 MF C6 H10 N2 O2
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT,
 CHEMCATS, CHEMLIST, CIN, CSCHEM, EMBASE, IPA, MEDLINE, NAPRALERT, PROMT,
 TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

335 REFERENCES IN FILE CA (1907 TO DATE)
 19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 340 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> E hydroxyectoine/CN

E1	1	HYDROXYECHINOFURAN B/CN
E2	1	HYDROXYECTOIN/CN
E3	0	--> HYDROXYECTOINE/CN
E4	1	HYDROXYEICOSATETRAENOIC ACID/CN
E5	1	HYDROXYELGENOL/CN
E6	1	HYDROXYELTENAC/CN
E7	1	HYDROXYEMODIN/CN
E8	2	HYDROXYEPHEDRINE/CN
E9	1	HYDROXYEPOXYCOLLININ I/CN
E10	1	HYDROXYEPOXYCOLLININ II/CN
E11	1	HYDROXYEREMOPHILONE/CN
E12	1	HYDROXYERGOTAMINE/CN

=> S e2

L2 1 HYDROXYECTOIN/CN

=> D L2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN

RN 165542-15-4 REGISTRY

ED Entered STN: 01 Aug 1995

CN 4-Pyrimidinecarboxylic acid, 1,4,5,6-tetrahydro-5-hydroxy-2-methyl-,
 (4S,5S)- (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 4-Pyrimidinecarboxylic acid, 1,4,5,6-tetrahydro-5-hydroxy-2-methyl-,
[S-(R*,R*)]-

OTHER NAMES:

CN (S,S)- β -Hydroxyectoine
 CN (S,S)-1,4,5,6-tetrahydro-5-hydroxy-2-methyl-4-pyrimidinecarboxylic acid
 CN β -Hydroxyectoine
 CN Hydroxyectoin
 CN Pyrostatin A
 CN Pyrostatine A
 FS STEREOSEARCH
 DR 162763-50-0
 MF C6 H10 N2 O3
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, TOXCENTER, USPAT2,
 USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

37 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 39 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FILE MEDICINE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
15.28	15.50

FULL ESTIMATED COST

FILE 'ADISCTI' ENTERED AT 20:04:29 ON 05 JUN 2009

COPYRIGHT (C) 2009 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 20:04:29 ON 05 JUN 2009

COPYRIGHT (C) 2009 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 20:04:29 ON 05 JUN 2009

COPYRIGHT (C) 2009 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 20:04:29 ON 05 JUN 2009

Copyright (c) 2009 The Thomson Corporation

FILE 'BIOTECHNO' COULD NOT BE ENTERED

FILE 'CAPLUS' ENTERED AT 20:04:29 ON 05 JUN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DDFB' COULD NOT BE ENTERED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' COULD NOT BE ENTERED

FILE 'DISSABS' ENTERED AT 20:04:29 ON 05 JUN 2009
COPYRIGHT (C) 2009 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' COULD NOT BE ENTERED

FILE 'DRUGMONOG2' ENTERED AT 20:04:29 ON 05 JUN 2009
COPYRIGHT (C) 2009 IMSWORLD Publications Ltd

FILE 'DRUGU' COULD NOT BE ENTERED

FILE 'EMBAL' ENTERED AT 20:04:29 ON 05 JUN 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 20:04:29 ON 05 JUN 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'ESBIOBASE' COULD NOT BE ENTERED

FILE 'IFIPAT' ENTERED AT 20:04:29 ON 05 JUN 2009
COPYRIGHT (C) 2009 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 20:04:29 ON 05 JUN 2009
COPYRIGHT (C) 2009 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 20:04:29 ON 05 JUN 2009
COPYRIGHT (C) 2009 IMSWORLD Publications Ltd

FILE 'IPA' ENTERED AT 20:04:29 ON 05 JUN 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'KOSMET' COULD NOT BE ENTERED

FILE 'LIFESCI' ENTERED AT 20:04:29 ON 05 JUN 2009
COPYRIGHT (C) 2009 Cambridge Scientific Abstracts (CSA)

FILE 'MEDLINE' ENTERED AT 20:04:29 ON 05 JUN 2009

FILE 'NAPRALERT' ENTERED AT 20:04:29 ON 05 JUN 2009
COPYRIGHT (C) 2009 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 20:04:29 ON 05 JUN 2009
COPYRIGHT (C) 2009 Gale Group. All rights reserved.

FILE 'NUTRACEUT' COULD NOT BE ENTERED

FILE 'PASCAL' COULD NOT BE ENTERED

FILE 'PCTGEN' COULD NOT BE ENTERED

FILE 'PHARMAML' COULD NOT BE ENTERED

FILE 'PHIN' ENTERED AT 20:04:29 ON 05 JUN 2009
COPYRIGHT (C) 2009 Informa UK Ltd.

FILE 'SCISEARCH' ENTERED AT 20:04:29 ON 05 JUN 2009

Copyright (c) 2009 The Thomson Corporation

FILE 'TOXCENTER' ENTERED AT 20:04:29 ON 05 JUN 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USGENE' COULD NOT BE ENTERED

FILE 'USPATFULL' ENTERED AT 20:04:29 ON 05 JUN 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 20:04:29 ON 05 JUN 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 20:04:29 ON 05 JUN 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> S L1 or L2
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
L3 893 L1 OR L2

=> S L3 and (neurodermatitis or eczema or (atopic dermatitis) or itchy or itch)
L4 21 L3 AND (NEURODERMATITIS OR ECZEMA OR (ATOPIC DERMATITIS) OR
ITCHY OR ITCH)

=> D L4 1-21 IBIB ABS

L4 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:636880 CAPLUS
DOCUMENT NUMBER: 148:569014
TITLE: Compositions for topical treatment of skin diseases
containing ectoin, urea or their derivs. and
St.-John's-wort extract
PATENT ASSIGNEE(S): Maria Clementine Martin Klosterfrau
Vertriebsgesellschaft Mbh, Germany
SOURCE: Ger. Gebrauchsmusterschrift, 16pp.
CODEN: GGXXFR
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 202007004981	U1	20080529	DE 2007-202007004981	20070404
DE 102007013857	A1	20080925	DE 2007-102007013857	20070320
WO 2008113400	A1	20080925	WO 2007-EP10791	20071211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: DE 2007-102007013857IA 20070320

AB The invention concerns pharmaceutical compns. for the treatment of skin diseases that contain a combination of (a) ectoin and/or at least one ectoin derivative; (b) urea and/or at least one urea derivative; and/or (c) ingredients of Hypericum perforatum L. Panthenol can be added. Ointments, creams, pastes, gels, lotions are prepared Thus a composition contained (weight/weight%): Med-Ectoin (highly purified from extremophilic bacteria) 5.0; allantoin 0.3; dexpanthenol 2.0; water 56.0; base cream to 100.

L4 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:673311 CAPLUS

DOCUMENT NUMBER: 143:158763

TITLE: Flavonoid complexes comprising cyclodextrins

INVENTOR(S): Wirth, Corinna; Roskopf, Ralf; Buchholz, Herwig

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068484	A1	20050728	WO 2004-EP14729	20041227
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 102004002787	A1	20050811	DE 2004-102004002787	20040119
EP 1718658	A1	20061108	EP 2004-804319	20041227
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1906204	A	20070131	CN 2004-80040675	20041227
JP 2007518750	T	20070712	JP 2006-549918	20041227
US 20070155695	A1	20070705	US 2006-586458	20060718
PRIORITY APPLN. INFO.:			DE 2004-102004002787A	20040119
			WO 2004-EP14729	W 20041227

OTHER SOURCE(S): MARPAT 143:158763

GI



AB The invention relates to complexes of specific flavonoid derivs. of formula (I), to preps. containing derivs. of this type, to corresponding methods for producing the flavonoid derivs. or preps. containing the latter and to their use, in particular for the care, preservation or improvement of the general condition of the skin or hair. In formula (I): Z1 to Z4 and Z6 to Z10 represent independently of one another H, OH, CH₃COO, alkoxy, hydroxyalkoxy, monoglycoside or oligoglycoside groups, whereby the alkoxy and hydroxyalkoxy groups can be branched or unbranched and can have between 1 and 18 C atoms; A-B represents 2 carbons joined by either a single or double bond; and Z5 represents a monoglycoside or oligoglycoside group, whereby at least one group, selected from specific benzo derivs., is bonded to said glycoside group by means of a resp. -O- group.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:182648 CAPLUS

DOCUMENT NUMBER: 142:280056

TITLE: Preparation of chromen-4-one derivatives for use in cosmetic and dermatological products

INVENTOR(S): Carola, Christophe; Buchholz, Herwig

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019197	A1	20050303	WO 2004-EP8043	20040719
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10337862	A1	20050317	DE 2003-10337862	20030818
EP 1656364	A1	20060517	EP 2004-741136	20040719
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 CN 1835940 A 20060920 CN 2004-80023579 20040719
 JP 2007502787 T 20070215 JP 2006-523547 20040719
 US 20060292093 A1 20061228 US 2006-568385 20060215
 PRIORITY APPLN. INFO.: DE 2003-10337862 A 20030818
 WO 2004-EP8043 W 20040719
 OTHER SOURCE(S): CASREACT 142:280056; MARPAT 142:280056
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. that are selected from the compds. of formulas I [R1, R2 = H, C(:O)R7, C(:O)OR7, (un)branced C1-20-alkyl, C3-20-alkenyl, C1-20-hydroxyalkyl (primary or secondary OH), C3-10-cycloalkyl, C3-12-cycloalkenyl; R3 = H, (un)branced C1-20-alkyl; R4 = H, OR8; R5, R6 = H, OH, (un)branced C1-20-alkyl, C3-20-alkenyl, C1-20-hydroxyalkyl; R7 = H, (un)branced C1-20-alkyl, polyhydroxy compd, (e.g., ascorbic acid, glycoside); R8 = H, (un)branced C1-20-alkyl] II and III, and to their production and use in cosmetic and dermatol. products. Thus, L-ascorb-6-yl 5,7-dihydroxy-4-oxo-4H-chromen-2-carboxylate (IV) was prepared from 2,4,6-trihydroxyacetophenone via cyclocondensation with EtO2CCOC1 in pyridine containing catalytic DMAP, saponification with Na2CO3 in EtOH, and esterification with (+)-L-ascorbic acid in the presence of H2SO4. Examples of dermatol. formulations containing IV are presented.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:155392 CAPLUS
 DOCUMENT NUMBER: 142:225267
 TITLE: Synthesis and use of chromene-4-one derivatives for the care of skin and hair
 INVENTOR(S): Carola, Christophe; Huber, Sylvia; Rosskopf, Ralf; Buchholz, Herwig
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: Eur. Pat. Appl., 42 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1508327	A1	20050223	EP 2004-15739	20040705
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
DE 10337863	A1	20050317	DE 2003-10337863	20030818
JP 2005060398	A	20050310	JP 2004-236984	20040817
US 20050043398	A1	20050224	US 2004-920202	20040818
WO 2008025368	A1	20080306	WO 2006-EP8474	20060830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 EP 2056782 A1 20090513 EP 2006-777117 20060830
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, RS
 US 20080027133 A1 20080131 US 2007-869192 20071009
 PRIORITY APPLN. INFO.: DE 2003-10337863 A 20030818
 US 2004-920202 A1 20040818
 WO 2006-EP8474 W 20060830

OTHER SOURCE(S): MARPAT 142:225267

AB The invention concerns the synthesis of chromene-4-one derivs. and their
 application in cosmetic and dermatol. compns. for protecting and treating
 skin and hair. Thus 5,7-diacetoxy-3-acetyl-2-methyl-chromene-4-one was
 prepared from 2,4,6-trihydroxyacetophenone and sodium acetate in acetic acid
 anhydride; the product was boiled with sodium carbonate to obtain
 5,7-dihydroxy-2-methyl-chromene-4-one. The antiinflammatory activity of
 5,7-dihydroxy-2-methyl-chromene-4-one was tested with the PGE2 assay. A
 W/O emulsion contained (weight/weight%): 5,7-dihydroxy-2-methyl-chromene-4-one
 5; UV-pearl, OMC 30; polyglyceryl-3-dimerate 3; Cera alba 0.3;
 hydrogenated castor oil 0.2; liquid paraffin 7; caprylic/capric triglyceride
 7; hexyl laurate 4; PVP/eicosene copolymer 2; propylene glycol 4;
 magnesium sulfate 0.6; tocopherol 0.5; cyclomethicone 0.5; propylparaben
 0.05; methylparaben 0.15; water to 100.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:29203 CAPLUS

DOCUMENT NUMBER: 142:141233

TITLE: Use of osmolytes obtained from extremophilic bacteria
 for producing medicaments for the external treatment
 of neurodermatitis

INVENTOR(S): Krutmann, Jean

PATENT ASSIGNEE(S): Bitop Aktiengesellschaft fuer Biotechnische
 Optimierung, Germany

SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002581	A1	20050113	WO 2004-EP7134	20040701
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10330243	A1	20050120	DE 2003-10330243	20030703
EP 1641459	A1	20060405	EP 2004-740505	20040701

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 JP 2009513506 T 20090402 JP 2006-518076 20040701
 US 20070122464 A1 20070531 US 2005-563586 20051230
 PRIORITY APPLN. INFO.: DE 2003-10330243 A 20030703
 WO 2004-EP7134 W 20040701

AB The invention relates to the use of osmolytes, in particular ectoine and hydroxyectoine, in addition to their pharmacol. compatible salts and/or derivs. with a similar action, for producing dermatol. prepn. such as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of neurodermatitis. Thus a W/O emulsion contained (weight/weight%): water 85; ectoin 1.0; fatty base 10.3; polyalcs. 3.2; thickening agents 0.3; preservatives 0.2.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 21 TOXCENTER COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:361916 TOXCENTER
 COPYRIGHT: Copyright 2009 ACS
 DOCUMENT NUMBER: CA14208141233R
 TITLE: Use of osmolytes obtained from extremophilic bacteria for producing medicaments for the external treatment of neurodermatitis
 AUTHOR(S): Krutmann, Jean
 CORPORATE SOURCE: ASSIGNEE: Bitop Aktiengesellschaft fuer Biotechnische Optimierung
 PATENT INFORMATION: WO 2005002581 A1 13 Jan 2005
 SOURCE: (2005) PCT Int. Appl., 25 pp.
 CODEN: PIXXD2.
 COUNTRY: GERMANY, FEDERAL REPUBLIC OF
 DOCUMENT TYPE: Patent
 FILE SEGMENT: CAPLUS
 OTHER SOURCE: CAPLUS 2005:29203
 LANGUAGE: German
 ENTRY DATE: Entered STN: May 2009
 Last Updated on STN: May 2009

AB The invention relates to the use of osmolytes, in particular ectoine and hydroxyectoine, in addition to their pharmacol. compatible salts and/or derivs. with a similar action, for producing dermatol. prepn. such as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of neurodermatitis. Thus a W/O emulsion contained (weight/weight%): water 85; ectoin 1.0; fatty base 10.3; polyalcs. 3.2; thickening agents 0.3; preservatives 0.2.

L4 ANSWER 7 OF 21 USPATFULL on STN
 ACCESSION NUMBER: 2008:30837 USPATFULL
 TITLE: USE OF CHROMEN-4-ONE DERIVATIVES
 INVENTOR(S): Carola, Christophe, Langen, GERMANY, FEDERAL REPUBLIC OF
 Buchholz, Herwig, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 Huber, Sylvia, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
 Roskopf, Ralf, Muenster, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080027133	A1	20080131
APPLICATION INFO.:	US 2007-869192	A1	20071009 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-920202, filed on 18 Aug 2004, PENDING		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	DE 2003-10337863	20030818
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1-16	
LINE COUNT:	2162	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention relates to the use of chromen-4-one derivatives of the formula I ##STR1##	

where R.sup.1 and R.sup.2 may be identical or different and are selected from H, --C(.dbd.O)--R.sup.7, --C(.dbd.O)--OR.sup.7, alkyl groups, alkenyl groups, hydroxyalkyl groups and/or cycloalkyl groups and/or cycloalkenyl groups, R.sup.3 is H or alkyl groups, R.sup.4 is H or OR.sup.8, R.sup.5 and R.sup.6 are selected from --H, --OH, alkyl groups, alkenyl groups and hydroxyalkyl groups, and R.sup.7 is H, alkyl groups, a polyhydroxyl compound, such as, preferably, an ascorbic acid radical or glycosidic radicals, and R.sup.8 is H or alkyl groups, where at least two of the substituents R.sup.1, R.sup.2 and R.sup.4-R.sup.6 are different from H or at least one substituent from R.sup.1 and R.sup.2 is --C(.dbd.O)--R.sup.7 or --C(.dbd.O)--OR.sup.7, for the care, preservation or improvement of the general state of the skin or hair.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 21 USPATFULL on STN
 ACCESSION NUMBER: 2007:177874 USPATFULL
 TITLE: Flavonoid complexes with cyclodextrins
 INVENTOR(S): Wirth, Corinna, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
 Roskopf, Ralf, Muenster, GERMANY, FEDERAL REPUBLIC OF
 Buchholz, Herwig, Frankfurt, GERMANY, FEDERAL REPUBLIC
 OF

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 20070155695	A1	20070705
APPLICATION INFO.:	US 2004-586458	A1	20041227 (10)
	WO 2004-EP14729		20041227
			20060718 PCT 371 date

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	DE 2004-102004	20040119
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2626	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to complexes of certain flavonoid derivatives, of the formula I compositions which comprise such derivatives, corresponding processes for the preparation of the flavonoid derivatives or of compositions comprising same, and the use thereof, in particular for the care, preservation or improvement of the general state of the skin or hair. Formula (1), in which Z.sub.1 to Z.sub.4 and Z.sub.6 to

Z.sub.10 each, independently of one another, denote H, OH, CH.sub.3COO, alkoxy, hydroxyalkoxy, mono- or oligoglycoside radicals and where the alkoxy and hydroxyalkoxy groups may be branched and unbranched and can have 1 to 18 C atoms. Formula (II) denotes, Z.sub.5 is a mono- or the oligoglycoside radical, where bonded to this glycoside radical, in each case via an --O-- group, is at least one radical selected from certain benzo molecule. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2007:140473 USPATFULL

TITLE: Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis

INVENTOR(S): Krutmann, Jean, Wegberg, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070122464	A1	20070531
APPLICATION INFO.:	US 2004-563586	A1	20040701 (10)
	WO 2004-EP7134		20040701
			20061213 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2003-10330243	20030703
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BERLINER & ASSOCIATES, 555 WEST FIFTH STREET, 31ST STREET, LOS ANGELES, CA, 90013, US	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	322	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of osmolytes, in particular ectoine and hydroxyectoine, as well as their pharmacologically compatible salts and/or derivatives having equivalent effects, for producing dermatological preparations such as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of neurodermatitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2007:18123 USPATFULL

TITLE: Use of an alkyl ether of hydroxystilbene for the treatment of dry skin

INVENTOR(S): Dalko, Maria, Gif S/Yvette, FRANCE

Rubinstenn, Gilles, Paris, FRANCE

PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE, 75008 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070015840	A1	20070118
APPLICATION INFO.:	US 2003-538662	A1	20031110 (10)
	WO 2003-EP12507		20031110
			20060807 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2002-16113	20021218

US 2003-438775P 20030109 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: C. IRVIN MCCLELLAND, OBLON, SPIVAK, MCCLELLAND, MAIER &
NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA,
22314, US
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1-20
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 508

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for the cosmetic treatment of
dry skin or of a dry scalp, comprising the topical application to the
skin or the scalp of a composition containing, in a physiologically
acceptable medium, at least one alkyl ether of hydroxystilbene with a
saturated or unsaturated, linear or branched C1-C6 alcohol. The
composition may be used for cosmetic purposes, for treating drying out
of the skin, in particular after the menopause, or for dermatological
purposes, for treating disorders associated with oligoseborrhoeic dry
skin, in particular forms of dermatitis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2006:340313 USPATFULL
TITLE: Chromen-4-one derivatives
INVENTOR(S): Carola, Christophe, Heidelberg, GERMANY, FEDERAL
REPUBLIC OF
Buchholz, Herwig, Frankfurt, GERMANY, FEDERAL REPUBLIC
OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20060292093	A1	20061228	
APPLICATION INFO.:	US 2004-568385	A1	20040719	(10)
	WO 2004-EP8043		20040719	
			20060215	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2003-10337862	20030818
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2064	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds that are selected from the compounds
of formulas (Ia)-(Ic) and to their production and use in cosmetic and
dermatological products. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2006:261094 USPATFULL
TITLE: Tricyclic quinoxaline and quinoline derivatives as UV
filters
INVENTOR(S): Pflucker, Frank, Darmstadt, GERMANY, FEDERAL REPUBLIC
OF
Schwarz, Michael, Weiterstadt, GERMANY, FEDERAL

REPUBLIC OF
Scholz, Volker, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Neunhoeffler, Hans, Muhlthal, GERMANY, FEDERAL REPUBLIC
OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060222607	A1	20061005
APPLICATION INFO.:	US 2006-446129	A1	20060605 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-471101, filed on 8 Sep 2003, PENDING A 371 of International Ser. No. WO 2002-EP1402, filed on 11 Feb 2002		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-10111728	20010309
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1-14	
LINE COUNT:	2045	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of quinoxaline derivatives of formula I, represented by formulas Ia and Ib, as photostable UV filters, in particular in cosmetic and pharmaceutical preparations for protecting the human epidermis or human hair against UV radiation, above all in the 280-400 nm range. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2005:50597 USPATFULL
TITLE: Use of chromen-4-one derivatives
INVENTOR(S): Carola, Christophe, Langen, GERMANY, FEDERAL REPUBLIC OF
Buchholz, Herwig, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Huber, Sylvia, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Roskopf, Ralf, Muenster, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050043398	A1	20050224
APPLICATION INFO.:	US 2004-920202	A1	20040818 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2003-10337863	20030818
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2275	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of chrome-4-one derivatives of the formula I ##STR1##

where R.sup.1 and R.sup.2 may be identical or different and are selected

from H, --C(.dbd.O)--R.sup.7, --C(.dbd.O)--OR.sup.7, alkyl groups, alkenyl groups, hydroxyalkyl groups and/or cycloalkyl groups and/or cycloalkenyl groups, R.sup.3 is H or alkyl groups, R.sup.4 is H or OR.sup.8, R.sup.5 and R.sup.6 are selected from --H, --OH, alkyl groups, alkenyl groups and hydroxyalkyl groups, and R.sup.7 is H, alkyl groups, a polyhydroxyl compound, such as, preferably, an ascorbic acid radical or glycosidic radicals, and R.sup.8 is H or alkyl groups, where at least two of the substituents R.sup.1, R.sup.2 and R.sup.4--R.sup.6 are different from H or at least one substituent from R.sup.1 and R.sup.2 is --C(.dbd.O)--R.sup.7 or --C(.dbd.O)--OR.sup.7, for the care, preservation or improvement of the general state of the skin or hair.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2004:133909 USPATFULL
 TITLE: Tricyclic quinoxaline derivatives as a uv filter
 INVENTOR(S): Pflucker, Frank, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
 Schwarz, Michael, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
 Scholz, Volker, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
 Neunhofer, Hans, Muhltal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040102446	A1	20040527
	US 7101537	B2	20060905
APPLICATION INFO.:	US 2003-471101	A1	20030908 (10)
	WO 2002-EP1402		20020211

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-10111728	20010309
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Millen White, Zelano & Branigan, Arlington Courthouse Plaza I, 2200 Clarendon Boulevard Suite 1400, Arlington, VA, 22201	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2112	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of quinoxaline derivatives of formula I, represented by formulas 1a and 1b, as photostable UV filters, in particular in cosmetic and pharmaceutical preparations for protecting the human epidermis or human hair against UV radiation, above all in the 280-400 nm range. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2004:63310 USPATFULL
 TITLE: Ectoin or ectoin derivatives and surfactants
 INVENTOR(S): Buenger, Joachim, Oetzberg-Hering, GERMANY, FEDERAL REPUBLIC OF
 Driller, Hans-Juergen, Gross-Umstadt, GERMANY, FEDERAL REPUBLIC OF
 Martin, Roland, Weinheim, GERMANY, FEDERAL REPUBLIC OF
 PATENT ASSIGNEE(S): Merck Patent GmbH, Darmstadt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040047828	A1	20040311
APPLICATION INFO.:	US 2003-620812	A1	20030717 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-744945, filed on 31 Jan 2001, GRANTED, Pat. No. US 6602514 A 371 of International Ser. No. WO 1999-EP5239, filed on 22 Jul 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19834817	19980801
	DE 1999-DE19911775	19990317
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	840	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of one or more compounds selected from the compounds of formulas (Ia) and (Ib), to the physiologically compatible salts of compounds of formulas (Ia) and (Ib), and to the stereoisomeric forms of the compounds of formulas (Ia) and (Ib), whereby R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n have the meanings cited in Claim Nr. 1. The compounds are used for producing a cosmetic formulation. The compounds are, for example, advantageously used for protecting cells, proteins and/or biomembranes of the human skin, for protecting the microflora of the human skin, for stabilizing the skin barrier, and/or for ameliorating effects of surfactants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2003:294868 USPATFULL
 TITLE: Preparation containing quinoxaline derivatives
 INVENTOR(S): Plucker, Frank, UNITED STATES
 Driller, Hansj?uuml,rgen, Gross-Umstadt, GERMANY, FEDERAL REPUBLIC OF
 Kirschbaum, Michael, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
 Scholz, Volker, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
 Neunhoefffer, Hans, M?uuml;hlal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030207886	A1	20031106
APPLICATION INFO.:	US 2002-221726	A1	20020916 (10)
	WO 2001-EP2517		20010306

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10013318	20000317
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	

LINE COUNT: 2434

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of quinoxaline derivatives as photostable UV filters in cosmetic and pharmaceutical preparations for protecting the human epidermis or human hair against UV radiation, especially in the 280-400 nm range.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2003:225277 USPATFULL

TITLE: Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care

INVENTOR(S): Elliott, Russell Phillip, Egham, UNITED KINGDOM
Saunders, Charles Winston, Fairfield, OH, UNITED STATES
Weisgerber, David John, Cincinnati, OH, UNITED STATES

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030157088	A1	20030821
APPLICATION INFO.:	US 2002-293100	A1	20021112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-338149P	20011113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224	
NUMBER OF CLAIMS:	51	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1599	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Leave-on personal care compositions comprising a stabilized enzyme, at least 30% water, less than 5% of an earth alkali metal salt, and an enzyme inhibitor having an inhibition constant ($K_{sub.1}$) from 10 nanomolar (nM) to 25,000 nM. Also, a method of providing a skin care benefits, e.g. skin feel and/or skin appearance, preferably skin moisturization, skin softness, and/or skin smoothness, comprising topically applying a safe and effective amount of the inventive compositions described herein to skin in need of such a skin care benefit. Further, a method of providing a consumer with a leave-on enzyme-containing personal care product, wherein the enzyme is inhibited and inactive on shelf, but is active on skin without the need for a separate re-activation step, preferably wherein the leave-on enzyme-containing personal care product comprises a one of the inventive compositions described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2003:209863 USPATFULL

TITLE: Use of ectoine or ectoine derivatives in cosmetic formulations

INVENTOR(S): Bunger, Joachim, Gross-Umstadt, GERMANY, FEDERAL REPUBLIC OF
Driller, Hans-Jurgen, Gross-Umstadt, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Martin, Roland, Weinheim, GERMANY, FEDERAL REPUBLIC OF
Merck Patent GmbH, Darmstadt, GERMANY, FEDERAL REPUBLIC
OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6602514	B1	20030805
	WO 2000007560		20000217
APPLICATION INFO.:	US 2001-744945		20010131 (9)
	WO 1999-EP5239		19990722

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19834817	19980801
	DE 1999-19911775	19990317
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Lamm, Marina	
LEGAL REPRESENTATIVE:	Millen, White, Zelano & Branigan, P.C.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	602	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of one or more compounds chosen from the compounds of the
formulae Ia and Ib ##STR1##

the physiologically compatible salts of the compounds of the formulae Ia and Ib and the stereoisomeric forms of the compounds of the formulae Ia and Ib, where R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n have the meanings given in claim 1, for the preparation of a cosmetic formulation is advantageously suitable, e.g., for protecting cells, proteins and/or biomembranes of the human skin, for protecting the microflora of the human skin, and/or for stabilizing the skin barrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2003:86818 USPATFULL

TITLE: Formulation for protection against oxidative stress
containing benzofuranone derivatives

INVENTOR(S): Pflucker, Frank, UNITED STATES
Buchholz, Herwig, Frankfurt, GERMANY, FEDERAL REPUBLIC
OF
Roskopf, Ralf, M?unster, GERMANY, FEDERAL REPUBLIC
OF
Bunger, Joachim, Gross-Umstadt, GERMANY, FEDERAL
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030060426	A1	20030327
	US 6903134	B2	20050607
APPLICATION INFO.:	US 2002-182385	A1	20020729 (10)
	WO 2001-EP652		20010122

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-100	20000128
	DE 2000-100	20001011
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON
BLVD., SUITE 1400, ARLINGTON, VA, 22201
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 2135

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a cosmetic or pharmaceutical formulation comprising at least one compound of formula (I). The cosmetics or pharmaceutical products are particularly suitable for the care of the skin in protecting against oxidative stress and ageing phenomena.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 21 USPAT2 on STN

ACCESSION NUMBER: 2004:133909 USPAT2
TITLE: Tricyclic quinoxaline and quinoline derivatives as a UV filter
INVENTOR(S): Pfluecker, Frank, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Schwarz, Michael, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
Scholz, Volker, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Neunhoeffer, Hans, Muehital, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Merck Patentgesellschaft, Darmstadt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7101537	B2	20060905
	WO 2002072583		20020919
APPLICATION INFO.:	US 2002-471101		20020211 (10)
	WO 2002-EP1402		20020211
			20030908 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-10111728	20010309
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Wilson, James O.	
ASSISTANT EXAMINER:	Tucker, Zachary C.	
LEGAL REPRESENTATIVE:	Millen, White, Zelano & Branigan, P.C.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	12	
LINE COUNT:	2208	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of quinoxaline derivatives of formula I, represented by formulas 1a and 1b, as photostable UV filters, in particular in cosmetic and pharmaceutical preparations for protecting the human epidermis or human hair against UV radiation, above all in the 280-400 nm range.

##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 21 USPAT2 on STN

ACCESSION NUMBER: 2003:86818 USPAT2
TITLE: Formulation comprising benzofuranone derivatives for protection against oxidative stress

INVENTOR(S): Pflucker, Frank, Darmstadt, GERMANY, FEDERAL REPUBLIC
OF
Buchholz, Herwig, Frankfurt, GERMANY, FEDERAL REPUBLIC
OF
Rosskopf, Ralf, Muenster, GERMANY, FEDERAL REPUBLIC OF
Bunger, Joachim, Gross-Umstadt, GERMANY, FEDERAL
REPUBLIC OF
PATENT ASSIGNEE(S): Merck Patent GmbH, Darmstadt, GERMANY, FEDERAL REPUBLIC
OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6903134	B2	20050607
	WO 2001055128		20010802
APPLICATION INFO.:	US 2002-182385		20010122 (10)
	WO 2001-EP652		20010122
			20020729 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10003785	20000128
	DE 2002-10050237	20001011
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Qazi, Sabiha	
LEGAL REPRESENTATIVE:	Millen, White, Zelano, Branigan, P.C.	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2008	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a cosmetic or pharmaceutical formulation comprising at least one compound of formula (I). The cosmetics or pharmaceutical products are particularly suitable for the care of the skin in protecting against oxidative stress and ageing phenomena.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> S L3 and (neurodermatitis or eczema or (atopic dermatitis))
UNMATCHED LEFT PARENTHESIS 'AND (NEURODERMA'
The number of right parentheses in a query must be equal to the number of left parentheses.

=> S L3 and (neurodermatitis or eczema or (atopic dermatitis))
L5 20 L3 AND (NEURODERMATITIS OR ECZEMA OR (ATOPIC DERMATITIS))

=> S L4 and py<2004
'2004' NOT A VALID FIELD CODE
15 FILES SEARCHED...
L6 6 L4 AND PY<2004

=> DUP REM L6
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DRUGMONOG2, IMSPRODUCT'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L6
L7 6 DUP REM L6 (0 DUPLICATES REMOVED)

=> D L7 1-6 IBIB ABS KWIC

L7 ANSWER 1 OF 6 USPAT2 on STN
ACCESSION NUMBER: 2004:133909 USPAT2

TITLE: Tricyclic quinoxaline and quinoline derivatives as a UV filter

INVENTOR(S): Pfluecker, Frank, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Schwarz, Michael, Weiterstadt, GERMANY, FEDERAL REPUBLIC OF
Scholz, Volker, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Neunhoeffler, Hans, Muehital, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Merck Patentgesellschaft, Darmstadt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 7101537	B2	20060905	
	WO 2002072583		20020919	<--
APPLICATION INFO.:	US 2002-471101		20020211	(10)
	WO 2002-EP1402		20020211	
			20030908	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-10111728	20010309
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Wilson, James O.	
ASSISTANT EXAMINER:	Tucker, Zachary C.	
LEGAL REPRESENTATIVE:	Millen, White, Zelano & Branigan, P.C.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	12	
LINE COUNT:	2208	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of quinoxaline derivatives of formula I, represented by formulas 1a and 1b, as photostable UV filters, in particular in cosmetic and pharmaceutical preparations for protecting the human epidermis or human hair against UV radiation, above all in the 280-400 nm range.

##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . is known that preparations of this type can be used, for example, for the therapy of psoriasis, various forms of eczema, irritative and toxic dermatitis, UV dermatitis and further allergic and/or inflammatory diseases of the skin and integumentary appendages. Preparations according. . .

IT 50652-76-1, 2-Hydroxy-5-methylaurophenone oxime 96702-03-3, Ectoin 165542-15-4, Hydroxyectoin 457899-12-6 (antioxidants stabilized by; preparation of quinoxaline derivs. for use as as UV filter stabilizers in cosmetic and pharmaceutical formulations)

L7 ANSWER 2 OF 6 USPAT2 on STN

ACCESSION NUMBER: 2003:86818 USPAT2

TITLE: Formulation comprising benzofuranone derivatives for protection against oxidative stress

INVENTOR(S): Pflucker, Frank, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Buchholz, Herwig, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Roskopf, Ralf, Muenster, GERMANY, FEDERAL REPUBLIC OF
Bunger, Joachim, Gross-Umstadt, GERMANY, FEDERAL

PATENT ASSIGNEE(S): REPUBLIC OF
Merck Patent GmbH, Darmstadt, GERMANY, FEDERAL REPUBLIC
OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6903134	B2	20050607	
	WO 2001055128		20010802	<--
APPLICATION INFO.:	US 2002-182385		20010122	(10)
	WO 2001-EP652		20010122	
			20020729	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10003785	20000128
	DE 2002-10050237	20001011
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Qazi, Sabiha	
LEGAL REPRESENTATIVE:	Millen, White, Zelano, Branigan, P.C.	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2008	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a cosmetic or pharmaceutical formulation comprising at least one compound of formula (I). The cosmetics or pharmaceutical products are particularly suitable for the care of the skin in protecting against oxidative stress and ageing phenomena.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . is known that preparations of this type can be used, for example, for the therapy of psoriasis, various forms of eczema, irritative and toxic dermatitis, UV dermatitis and further allergic and/or inflammatory diseases of the skin and integumentary appendages. Formulations according. . .

IT 50-81-7, Vitamin C, biological studies 50-81-7D, Vitamin C, derivs. 112-92-5, Stearyl alcohol 118-56-9, 3,3,5-Trimethylcyclohexyl salicylate 131-57-7, 2-Hydroxy-4-methoxybenzophenone 506-03-6, Chimyl alcohol 593-31-7, Selachyl alcohol 629-96-9, Arachidyl alcohol 661-19-8, Behenyl alcohol 1323-39-3, Propylene glycol monostearate 1338-39-2, Sorbitan monolaurate 5466-77-3 6197-30-4, 2-Ethylhexyl 2-Cyano-3,3-diphenylacrylate 9005-00-9, Steareth-2 12694-22-3, Diglyceryl monostearate 21245-02-3, 2-Ethylhexyl 4-(dimethylamino)benzoate 25496-72-4, Glyceryl monooleate 26402-22-2, Glyceryl monocaprylate 26402-26-6, Glyceryl monocaprylate 27194-74-7, Propylene glycol monolaurate 27195-16-0, Saccharose distearate 27214-38-6, Glyceryl monomyristate 27215-38-9, Glyceryl monolaurate 27503-81-7, 2-Phenylbenzimidazole-5-sulfonic acid 31565-12-5, Propylene glycol monocaprylate 31566-31-1, Glyceryl monostearate 36653-82-4, Cetyl alcohol 36861-47-9 40867-42-3 54392-26-6, Sorbitan monoisostearate 60177-36-8, Sorbitan monocaprylate 63250-25-9, 4-Isopropylidibenzoylmethane 66085-00-5, Glyceryl monoisostearate 68171-38-0, Propylene glycol monoisostearate 70356-09-1, 1-(4-tert-Butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione 81752-33-2, Diglyceryl monoisostearate 96702-03-3 165542-15-4 179799-69-0, Isobehenyl alcohol 226418-81-1, Sorbitan monoisoooleate (benzofuranone formulation for protection against oxidative stress)

L7 ANSWER 3 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2003:294868 USPATFULL

TITLE: Preparation containing quinoxaline derivatives
 INVENTOR(S): Plucker, Frank, UNITED STATES
 Driller, Hansj?uuml,rgen, Gross-Umstadt, GERMANY,
 FEDERAL REPUBLIC OF
 Kirschbaum, Michael, Weiterstadt, GERMANY, FEDERAL
 REPUBLIC OF
 Scholz, Volker, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
 Neunhoeffler, Hans, M?uuml;hlal, GERMANY, FEDERAL
 REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20030207886	A1	20031106	<--
APPLICATION INFO.:	US 2002-221726	A1	20020916	(10)
	WO 2001-EP2517		20010306	

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10013318	20000317
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2434	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of quinoxaline derivatives as photostable UV filters in cosmetic and pharmaceutical preparations for protecting the human epidermis or human hair against UV radiation, especially in the 280-400 nm range.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . is known that preparations of this type can be used, for example, for the therapy of psoriasis, various forms of eczema, irritative and toxic dermatitis, UV dermatitis and further allergic and/or inflammatory diseases of the skin and integumentary appendages. Preparations according. . .

IT 118-56-9 131-57-7 1504-78-5 2213-63-0 5466-77-3 6197-30-4
 6323-89-3 6640-47-7, 2,3-Quinoxalinediamine 13481-33-9 17911-93-2
 21245-02-3 25871-18-5 27503-81-7, 2-Phenylbenzimidazole-5-sulfonic
 acid 27739-37-3, 2,2'-Biquinoxaline 35552-76-2 36818-07-2
 36856-91-4 49679-45-0 50652-76-1 56404-42-3 62294-86-4
 63250-25-9 70356-09-1 75163-15-4 75163-16-5 75470-77-8
 83451-39-2 84199-29-1 96702-03-3, Ectoin 97065-23-1
 99565-84-1 100962-02-5 101101-68-2 101576-66-3 112080-12-3
 117764-56-4 127376-18-5 127376-24-3 128499-91-2 143076-31-7
 156967-94-1 199275-08-6 205114-37-0 213467-54-0 361389-97-1
 361390-03-6 361390-04-7 361390-05-8 361390-06-9 361390-07-0
 361390-08-1 361390-09-2 361390-10-5 361390-11-6 361390-12-7
 361390-13-8 361390-14-9 361390-15-0 361390-16-1 361390-17-2
 361390-18-3 361390-19-4 361390-20-7 361390-21-8 361390-22-9
 361390-23-0 361390-24-1 361390-25-2 361390-26-3 361390-27-4
 361390-28-5 361390-29-6 361390-30-9 361390-31-0 361390-32-1
 361390-33-2 361390-34-3 361390-35-4 361390-36-5 361390-37-6
 361390-38-7 361390-39-8 361390-40-1 361390-41-2 361390-42-3
 361390-43-4 361390-44-5 361390-45-6 361390-46-7 362518-85-2
 362518-86-3 362518-87-4

(preps. containing quinoxaline derivs. as photostable UV filters for cosmetic and pharmaceutical use)

L7 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:225277 USPATFULL

TITLE: Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care

INVENTOR(S): Elliott, Russell Phillip, Egham, UNITED KINGDOM
Saunders, Charles Winston, Fairfield, OH, UNITED STATES
Weisgerber, David John, Cincinnati, OH, UNITED STATES

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20030157088	A1	20030821	<--
APPLICATION INFO.:	US 2002-293100	A1	20021112	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-338149P	20011113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224	

NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
LINE COUNT: 1599

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Leave-on personal care compositions comprising a stabilized enzyme, at least 30% water, less than 5% of an earth alkali metal salt, and an enzyme inhibitor having an inhibition constant ($K_{sub.1}$) from 10 nanomolar (nM) to 25,000 nM. Also, a method of providing a skin care benefits, e.g. skin feel and/or skin appearance, preferably skin moisturization, skin softness, and/or skin smoothness, comprising topically applying a safe and effective amount of the inventive compositions described herein to skin in need of such a skin care benefit. Further, a method of providing a consumer with a leave-on enzyme-containing personal care product, wherein the enzyme is inhibited and inactive on shelf, but is active on skin without the need for a separate re-activation step, preferably wherein the leave-on enzyme-containing personal care product comprises a one of the inventive compositions described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . and may eventually permit the surfactant, solvent, or agents carried by them, to interact with the keratin, causing irritation. Dry, itchy, or flaky skin may result from failure to maintain a proper water gradient across the stratum corneum. Most of the . . . outermost portions of stratum corneum to properly plasticize the tissue, and the skin begins to dry up, flake, and/or become itchy.

IT 50-81-7, Vitamin C, biological studies 56-40-6, Glycine, biological studies 56-41-7, Alanine, biological studies 56-45-1, Serine, biological studies 56-81-5, Glycerin, biological studies 56-86-0D, Glutamic acid, acyl derivs. 58-08-2, Caffeine, biological studies 58-95-7, Tocopherol acetate 64-18-6D, Formic acid, salts 65-23-6, Pyridoxine 68-26-8, Retinol 79-14-1D, Glycolic acid, salts 79-81-2, Retinol palmitate 81-13-0, Panthenol 83-67-0, Theobromine 87-99-0, Xylitol 97-59-6, Allantoin 98-80-6, Phenylboronic acid 98-92-0, Niacinamide 107-36-8D, Isethionic acid, alkyl esters 107-97-1D, Sarcosine, alkyl derivs. 110-15-6D, Succinic acid, salts 110-63-4, Butane 1,4-diol, biological studies 124-04-9D, Adipic acid, salts

141-53-7D, Sodium formate, salts 141-82-2D, Malonic acid, salts
 147-85-3, Proline, biological studies 147-85-3D, L-Proline, derivs.
 149-32-6, Erythritol 151-21-3, Sodium lauryl sulfate, biological
 studies 302-79-4, Retinoic acid 407-64-7, γ -Butyrobetaine
 515-69-5, α -Bisabolol 541-15-1, Carnitine 1184-78-7,
 Trimethylamine oxide 1406-16-2, Vitamin D 1406-18-4, Vitamin E
 1932-50-9, Potassium glycolate 2235-54-3, Ammonium lauryl sulfate
 3416-24-8, Glucosamine 4426-47-5, Butylboronic acid 4602-84-0,
 Farnesol 5704-04-1, Tricine 6458-06-6, β -Alanine betaine
 7069-42-3, Retinyl propionate 7664-38-2D, Phosphoric acid, monoalkyl
 esters 7664-93-9D, Sulfuric acid, alkyl ethers or esters, salts
 9003-11-6 9004-82-4, Sodium laureth sulfate 9014-01-1D, Subtilisin,
 engineered recombinant forms 10043-35-3, Boric acid, biological studies
 16068-46-5, Potassium phosphate 17087-29-5, Alanine betaine
 23284-33-5, Lysine betaine 25322-68-3, Polyethylene glycol
 25322-68-3D, Polyethylene glycol, alkyl ethers 25323-24-4, Hexanetriol
 26100-47-0, Ammonium acrylate-acrylamide copolymer 27836-64-2, Lauryl
 glucoside 31904-60-6, Butanetetrol 32612-48-9, Ammonium laureth
 sulfate 33403-10-0, Potassium lauryl phosphate 43119-47-7, Tocopherol
 nicotinate 53948-31-5, Valine betaine 56755-22-7, Phenylalanine
 betaine 56987-64-5, Glutamic acid betaine 58846-77-8, Decyl glucoside
 66101-16-4 73573-88-3, Mevastatin 74563-64-7, Phytantriol
 75330-75-5, Lovastatin 87199-17-5, p-Formylphenylboronic acid
 96702-03-3, Ectoin 108910-78-7, Magnesium ascorbyl phosphate
 129499-78-1 156028-14-7, Sodium lauroamphoacetate 165542-15-4
 , HydroxyEctoin 214047-00-4 528569-57-5 528569-58-6 528569-59-7
 528569-60-0

(topical cosmetic compns. containing enzymes stabilized with inhibitors)

L7 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:86818 USPATFULL

TITLE: Formulation for protection against oxidative stress
 containing benzofuranone derivatives

INVENTOR(S): Pflucker, Frank, UNITED STATES
 Buchholz, Herwig, Frankfurt, GERMANY, FEDERAL REPUBLIC
 OF
 Roskopf, Ralf, M?uuml;nster, GERMANY, FEDERAL REPUBLIC
 OF
 Bunger, Joachim, Gross-Umstadt, GERMANY, FEDERAL
 REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20030060426	A1	20030327	<--
	US 6903134	B2	20050607	
APPLICATION INFO.:	US 2002-182385	A1	20020729	(10)
	WO 2001-EP652		20010122	

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-100	20000128
	DE 2000-100	20001011
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2135	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a cosmetic or pharmaceutical formulation
 comprising at least one compound of formula (I). The cosmetics or

pharmaceutical products are particularly suitable for the care of the skin in protecting against oxidative stress and ageing phenomena.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . is known that preparations of this type can be used, for example, for the therapy of psoriasis, various forms of eczema, irritative and toxic dermatitis, UV dermatitis and further allergic and/or inflammatory diseases of the skin and integumentary appendages. Formulations according. . .

IT 50-81-7, Vitamin C, biological studies 50-81-7D, Vitamin C, derivs. 112-92-5, Stearyl alcohol 118-56-9, 3,3,5-Trimethylcyclohexyl salicylate 131-57-7, 2-Hydroxy-4-methoxybenzophenone 506-03-6, Chimyl alcohol 593-31-7, Selachyl alcohol 629-96-9, Arachidyl alcohol 661-19-8, Behenyl alcohol 1323-39-3, Propylene glycol monostearate 1338-39-2, Sorbitan monolaurate 5466-77-3 6197-30-4, 2-Ethylhexyl 2-Cyano-3,3-diphenylacrylate 9005-00-9, Steareth-2 12694-22-3, Diglyceryl monostearate 21245-02-3, 2-Ethylhexyl 4-(dimethylamino)benzoate 25496-72-4, Glyceryl monooleate 26402-22-2, Glyceryl monocaprylate 26402-26-6, Glyceryl monocaprylate 27194-74-7, Propylene glycol monolaurate 27195-16-0, Saccharose distearate 27214-38-6, Glyceryl monomyristate 27215-38-9, Glyceryl monolaurate 27503-81-7, 2-Phenylbenzimidazole-5-sulfonic acid 31565-12-5, Propylene glycol monocaprylate 31566-31-1, Glyceryl monostearate 36653-82-4, Cetyl alcohol 36861-47-9 40867-42-3 54392-26-6, Sorbitan monoisostearate 60177-36-8, Sorbitan monocaprylate 63250-25-9, 4-Isopropylidibenzoylmethane 66085-00-5, Glyceryl monoisostearate 68171-38-0, Propylene glycol monoisostearate 70356-09-1, 1-(4-tert-Butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione 81752-33-2, Diglyceryl monoisostearate 96702-03-3 165542-15-4 179799-69-0, Isobehenyl alcohol 226418-81-1, Sorbitan monoisoooleate (benzofuranone formulation for protection against oxidative stress)

L7 ANSWER 6 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:209863 USPATFULL

TITLE: Use of ectoine or ectoine derivatives in cosmetic formulations

INVENTOR(S): Bunger, Joachim, Gross-Umstadt, GERMANY, FEDERAL REPUBLIC OF
Driller, Hans-Jurgen, Gross-Umstadt, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Martin, Roland, Weinheim, GERMANY, FEDERAL REPUBLIC OF
Merck Patent GmbH, Darmstadt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
	-----	----	-----	
PATENT INFORMATION:	US 6602514	B1	20030805	<--
	WO 2000007560		20000217	<--
APPLICATION INFO.:	US 2001-744945		20010131	(9)
	WO 1999-EP5239		19990722	

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	DE 1998-19834817	19980801
	DE 1999-19911775	19990317

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Dees, Jose' G.

ASSISTANT EXAMINER: Lamm, Marina

LEGAL REPRESENTATIVE: Millen, White, Zelano & Branigan, P.C.

NUMBER OF CLAIMS: 7

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 602
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of one or more compounds chosen from the compounds of the formulae Ia and Ib ##STR1##

the physiologically compatible salts of the compounds of the formulae Ia and Ib and the stereoisomeric forms of the compounds of the formulae Ia and Ib, where R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n have the meanings given in claim 1, for the preparation of a cosmetic formulation is advantageously suitable, e.g., for protecting cells, proteins and/or biomembranes of the human skin, for protecting the microflora of the human skin, and/or for stabilizing the skin barrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . of microorganisms increases in the case of moist skin, e.g. as a result of inflammatory changes in the case of eczema, by up to 1000-fold.

IT 96702-03-3 165542-15-4
(cosmetic formulations containing ectoin or ectoin derivs.)

=> S L4 and pd<2006
7 FILES SEARCHED...
14 FILES SEARCHED...
15 FILES SEARCHED...
'2006' NOT A VALID FIELD CODE
'2006' NOT A VALID FIELD CODE
20 FILES SEARCHED...
L8 14 L4 AND PD<2006

=> S L8 not L7
L9 8 L8 NOT L7

=> DUP REM L9
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DRUGMONOG2, IMSPRODUCT'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L9
L10 7 DUP REM L9 (1 DUPLICATE REMOVED)

=> D L10 1-7 IBIB ABS KWIC

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2005:29203 CAPLUS
DOCUMENT NUMBER: 142:141233
TITLE: Use of osmolytes obtained from extremophilic bacteria for producing medicaments for the external treatment of neurodermatitis
INVENTOR(S): Krutmann, Jean
PATENT ASSIGNEE(S): Bitop Aktiengesellschaft fuer Biotechnische Optimierung, Germany
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2005002581 A1 20050113 WO 2004-EP7134 20040701 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG
DE 10330243 A1 20050120 DE 2003-10330243 20030703 <--
EP 1641459 A1 20060405 EP 2004-740505 20040701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
JP 2009513506 T 20090402 JP 2006-518076 20040701
US 20070122464 A1 20070531 US 2005-563586 20051230
PRIORITY APPLN. INFO.: DE 2003-10330243 A 20030703
WO 2004-EP7134 W 20040701

AB The invention relates to the use of osmolytes, in particular ectoine and hydroxyectoine, in addition to their pharmacol. compatible salts and/or derivs. with a similar action, for producing dermatol. prepn. such as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of neurodermatitis. Thus a W/O emulsion contained (weight/weight%): water 85; ectoin 1.0; fatty base 10.3; polyalcs. 3.2; thickening agents 0.3; preservatives 0.2.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Use of osmolytes obtained from extremophilic bacteria for producing medicaments for the external treatment of neurodermatitis

PI WO 2005002581 A1 20050113

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002581	A1	20050113	WO 2004-EP7134	20040701 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10330243	A1	20050120	DE 2003-10330243	20030703 <--
EP 1641459	A1	20060405	EP 2004-740505	20040701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2009513506	T	20090402	JP 2006-518076	20040701
US 20070122464	A1	20070531	US 2005-563586	20051230

AB . . . as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of neurodermatitis. Thus a W/O emulsion contained (weight/weight%): water 85; ectoin 1.0; fatty base 10.3; polyalcs. 3.2; thickening agents 0.3; preservatives 0.2.

ST osmolyte extremophilic bacteria neurodermatitis cream ectoin hydroxyectoin

IT Analgesics
Anti-inflammatory agents

Antibiotics

Fungicides

(addnl. component; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)

IT Glucocorticoids

RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(addnl. component; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)

IT Pruritus

(antiitching agents, addnl. component; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)

IT Cosmetics

(creams; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis
)

IT Cosmetics

Drug delivery systems

(emulsions; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis
)

IT Eubacteria

(extremophilic; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)

IT Drug delivery systems

(hydrogels; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis
)

IT Cosmetics

Drug delivery systems

(lotions; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis
)

IT Dermatitis

(neurodermatitis; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)

IT Emulsions

(oil-in-water; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)

IT Drug delivery systems

(ointments, creams; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)

IT Drug delivery systems

(ointments; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis
)

IT Cosmetics

Drug delivery systems

(sprays; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis
)

IT Drug delivery systems

(topical; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis
)

IT Osmolytes
 (use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)

IT Emulsions
 (water-in-oil; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)


IT 361540-77-4, Calcineurin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor, addnl. component; use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)

IT 6418-92-4 88280-54-0 96702-03-3, Ectoine 96702-03-3D
 , Ectoine, salts 117229-60-4 117229-60-4D, salts 143491-08-1
 164324-35-0, Firoin 240417-63-4, Firoin A 438624-63-6
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (use of osmolytes obtained from extremophilic bacteria for producing medicaments for external treatment of neurodermatitis)

L10 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:673311 CAPLUS
 DOCUMENT NUMBER: 143:158763
 TITLE: Flavonoid complexes comprising cyclodextrins
 INVENTOR(S): Wirth, Corinna; Roskopf, Ralf; Buchholz, Herwig
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 118 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068484	A1	20050728	WO 2004-EP14729	20041227 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 102004002787	A1	20050811	DE 2004-102004002787	20040119 <--
EP 1718658	A1	20061108	EP 2004-804319	20041227
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1906204	A	20070131	CN 2004-80040675	20041227
JP 2007518750	T	20070712	JP 2006-549918	20041227
US 20070155695	A1	20070705	US 2006-586458	20060718
PRIORITY APPLN. INFO.:			DE 2004-102004002787A	20040119
			WO 2004-EP14729	W 20041227
OTHER SOURCE(S):	MARPAT 143:158763			
GI				



AB The invention relates to complexes of specific flavonoid derivs. of formula (I), to preps. containing derivs. of this type, to corresponding methods for producing the flavonoid derivs. or preps. containing the latter and to their use, in particular for the care, preservation or improvement of the general condition of the skin or hair. In formula (I): Z1 to Z4 and Z6 to Z10 represent independently of one another H, OH, CH₃COO, alkoxy, hydroxyalkoxy, monoglycoside or oligoglycoside groups, whereby the alkoxy and hydroxyalkoxy groups can be branched or unbranched and can have between 1 and 18 C atoms; A-B represents 2 carbons joined by either a single or double bond; and Z5 represents a monoglycoside or oligoglycoside group, whereby at least one group, selected from specific benzo derivs., is bonded to said glycoside group by means of a resp. -O- group.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI	WO 2005068484	A1	20050728			
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2005068484	A1	20050728	WO 2004-EP14729	20041227 <--	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	DE 102004002787	A1	20050811	DE 2004-102004002787	20040119 <--	
	EP 1718658	A1	20061108	EP 2004-804319	20041227	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS		
	CN 1906204	A	20070131	CN 2004-80040675	20041227	
	JP 2007518750	T	20070712	JP 2006-549918	20041227	
	US 20070155695	A1	20070705	US 2006-586458	20060718	
IT	Anti-inflammatory agents					
	Antioxidants					
	Eczema					
	Extraction					
	Food additives					
	Hair preparations					
	Human					
	Pruritus					
	Sunscreens					
	(flavonoid complexes comprising cyclodextrins)					
IT	Dermatitis					

(neurodermatitis; flavonoid complexes comprising cyclodextrins)

IT 7585-39-9, β -Cyclodextrin 10016-20-3, α -Cyclodextrin
 12619-70-4D, Cyclodextrins, derivs. 17465-86-0, γ -Cyclodextrin
 20316-62-5 56317-05-6 96702-03-3, Ectoin 104987-11-3,
 Tacrolimus
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (flavonoid complexes comprising cyclodextrins)

L10 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:182648 CAPLUS
 DOCUMENT NUMBER: 142:280056
 TITLE: Preparation of chromen-4-one derivatives for use in
 cosmetic and dermatological products
 INVENTOR(S): Carola, Christophe; Buchholz, Herwig
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019197	A1	20050303	WO 2004-EP8043	20040719 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10337862	A1	20050317	DE 2003-10337862	20030818 <--
EP 1656364	A1	20060517	EP 2004-741136	20040719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1835940	A	20060920	CN 2004-80023579	20040719
JP 2007502787	T	20070215	JP 2006-523547	20040719
US 20060292093	A1	20061228	US 2006-568385	20060215
PRIORITY APPLN. INFO.:			DE 2003-10337862	A 20030818
			WO 2004-EP8043	W 20040719
OTHER SOURCE(S):			CASREACT 142:280056; MARPAT 142:280056	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. that are selected from the compds. of
 formulas I [R1, R2 = H, C(:O)R7, C(:O)OR7, (un)branched C1-20-alkyl,
 C3-20-alkenyl, C1-20-hydroxyalkyl (primary or secondary OH),
 C3-10-cycloalkyl, C3-12-cycloalkenyl; R3 = H, (un)branched C1-20-alkyl; R4
 = H, OR8; R5, R6 = H, OH, (un)branched C1-20-alkyl, C3-20-alkenyl,
 C1-20-hydroxyalkyl; R7 = H, (un)branched C1-20-alkyl, polyhydroxy compd,
 (e.g., ascorbic acid, glycoside); R8 = H, (un)branched C1-20-alkyl] II and
 III, and to their production and use in cosmetic and dermatol. products.

Thus, L-ascorb-6-yl 5,7-dihydroxy-4-oxo-4H-chromen-2-carboxylate (IV) was prepared from 2,4,6-trihydroxyacetophenone via cyclocondensation with EtO₂CCOCl in pyridine containing catalytic DMAP, saponification with Na₂CO₃ in EtOH,

and esterification with (+)-L-ascorbic acid in the presence of H₂SO₄.

Examples of dermatol. formulations containing IV are presented.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2005019197 A1 20050303
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2005019197 A1 20050303 WO 2004-EP8043 20040719 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10337862 A1 20050317 DE 2003-10337862 20030818 <--

EP 1656364 A1 20060517 EP 2004-741136 20040719

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

CN 1835940 A 20060920 CN 2004-80023579 20040719

JP 2007502787 T 20070215 JP 2006-523547 20040719

US 20060292093 A1 20061228 US 2006-568385 20060215

IT Eczema
Hair, disease
Keratosis
Papilloma
Psoriasis
Wart

(therapeutics; preparation of chromen-4-one derivs. for use in cosmetic and dermatol. products)

IT 289-95-2D, Pyrimidine, carboxylic acid derivs. 96702-03-3,
Ectoin

RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)

(companion drug; preparation of chromen-4-one derivs. for use in cosmetic and dermatol. products)

L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:155392 CAPLUS

DOCUMENT NUMBER: 142:225267

TITLE: Synthesis and use of chromene-4-one derivatives for the care of skin and hair

INVENTOR(S): Carola, Christophe; Huber, Sylvia; Roskopf, Ralf; Buchholz, Herwig

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Eur. Pat. Appl., 42 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

EP 1508327	A1	20050223	EP 2004-15739	20040705 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
DE 10337863	A1	20050317	DE 2003-10337863	20030818 <--
JP 2005060398	A	20050310	JP 2004-236984	20040817 <--
US 20050043398	A1	20050224	US 2004-920202	20040818 <--
WO 2008025368	A1	20080306	WO 2006-EP8474	20060830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2056782	A1	20090513	EP 2006-777117	20060830
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20080027133	A1	20080131	US 2007-869192	20071009
PRIORITY APPLN. INFO.:				
			DE 2003-10337863	A 20030818
			US 2004-920202	A1 20040818
			WO 2006-EP8474	W 20060830

OTHER SOURCE(S): MARPAT 142:225267

AB The invention concerns the synthesis of chromene-4-one derivs. and their application in cosmetic and dermatol. compns. for protecting and treating skin and hair. Thus 5,7-diacetoxy-3-acetyl-2-methyl-chromene-4-one was prepared from 2,4,6-trihydroxyacetophenone and sodium acetate in acetic acid anhydride; the product was boiled with sodium carbonate to obtain 5,7-dihydroxy-2-methyl-chromene-4-one. The antiinflammatory activity of 5,7-dihydroxy-2-methyl-chromene-4-one was tested with the PGE2 assay. A W/O emulsion contained (weight/weight%): 5,7-dihydroxy-2-methyl-chromene-4-one 5; UV-pearl, OMC 30; polyglyceryl-3-dimerate 3; Cera alba 0.3; hydrogenated castor oil 0.2; liquid paraffin 7; caprylic/capric triglyceride 7; hexyl laurate 4; PVP/eicosene copolymer 2; propylene glycol 4; magnesium sulfate 0.6; tocopherol 0.5; cyclomethicone 0.5; propylparaben 0.05; methylparaben 0.15; water to 100.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI	EP 1508327	A1	20050223	EP 2004-15739	20040705 <--
	PATENT NO. KIND DATE APPLICATION NO. DATE				

PI	EP 1508327	A1	20050223	EP 2004-15739	20040705 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
	DE 10337863	A1	20050317	DE 2003-10337863	20030818 <--
	JP 2005060398	A	20050310	JP 2004-236984	20040817 <--
	US 20050043398	A1	20050224	US 2004-920202	20040818 <--
	WO 2008025368	A1	20080306	WO 2006-EP8474	20060830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,					

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 EP 2056782 A1 20090513 EP 2006-777117 20060830
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, RS
 US 20080027133 A1 20080131 US 2007-869192 20071009
 IT Anti-inflammatory agents
 Eczema
 Hair
 Hair preparations
 Keratosis
 Nail (anatomical), disease
 Papilloma
 Psoriasis
 Skin
 Skin, disease
 Sunscreens
 Wart
 (synthesis and use of chromene-4-one derivs. for care of skin and hair)
 IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 58-95-7,
 Tocopherol acetate 59-67-6, Nicotinic acid, biological studies
 79-83-4, Pantothenic acid 118-56-9, 3,3,5-Trimethylcyclohexylsalicylate
 131-57-7, 2-Hydroxy-4-methoxybenzophenone 1022-78-2 5997-53-5
 6197-30-4, Acrylic acid, 2-cyano-3,3-diphenyl-, 2-ethylhexyl ester
 7732-18-5, Water, biological studies 10020-01-6 10191-41-0,
 DL- α -Tocopherol 24672-78-4 27457-25-6D, Pyrimidinecarboxylic
 acid, derivs. 27503-81-7, 2-Phenylbenzimidazole-5-sulfonic acid
 36861-47-9, 3-(4-Methylbenzylidene)-dl-camphor 42059-55-2 58817-05-3
 63250-25-9, 4-Isopropylidibenzoylmethane 70356-09-1,
 1-(4-Methoxyphenyl)-3-(4-tert-butylphenyl)propane-1,3-dione
 96702-03-3, Ectoin 150668-35-2 158099-19-5 841277-59-6
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (synthesis and use of chromene-4-one derivs. for care of skin and hair)

L10 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:50597 USPATFULL
 TITLE: Use of chromen-4-one derivatives
 INVENTOR(S): Carola, Christophe, Langen, GERMANY, FEDERAL REPUBLIC
 OF
 Buchholz, Herwig, Frankfurt, GERMANY, FEDERAL REPUBLIC
 OF
 Huber, Sylvia, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
 Roskopf, Ralf, Muenster, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20050043398	A1	20050224	<--
APPLICATION INFO.:	US 2004-920202	A1	20040818	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2003-10337863	20030818
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2275	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of chrome-4-one derivatives of the formula I ##STR1##

where R.sup.1 and R.sup.2 may be identical or different and are selected from H, --C(.dbd.O)--R.sup.7, --C(.dbd.O)--OR.sup.7, alkyl groups, alkenyl groups, hydroxyalkyl groups and/or cycloalkyl groups and/or cycloalkenyl groups, R.sup.3 is H or alkyl groups, R.sup.4 is H or OR.sup.8, R.sup.5 and R.sup.6 are selected from --H, --OH, alkyl groups, alkenyl groups and hydroxyalkyl groups, and R.sup.7 is H, alkyl groups, a polyhydroxyl compound, such as, preferably, an ascorbic acid radical or glycosidic radicals, and R.sup.8 is H or alkyl groups, where at least two of the substituents R.sup.1, R.sup.2 and R.sup.4--R.sup.6 are different from H or at least one substituent from R.sup.1 and R.sup.2 is --C(.dbd.O)--R.sup.7 or --C(.dbd.O)--OR.sup.7, for the care, preservation or improvement of the general state of the skin or hair.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . other defects of keratinisation, in particular ichthyosis, ichthyosiform states, Darier's disease, keratosis palmoplantaris, leukoplasia, leukoplasiform states, skin and mucosal (buccal) eczema (lichen), for the treatment of other skin diseases which are associated with defective keratinisation and have an inflammatory and/or immunoallergic. . . of psoriasis relating to the skin, mucous membranes and finger- and toenails, and psoriatic rheumatism and skin atopy, such as eczema, or respiratory atopy, or also hypertrophy of the gums, and for the prophylaxis and/or treatment of all benign or malignant. . .

SUMM . . . 304 802. The compositions are suitable for the treatment of skin, in particular for the treatment of dermatoses, including atopic eczema.

SUMM . . . of psoriasis which affect the skin, mucous membranes and fingers and toenails, and psoriatic rheumatism and skin atopy, such as eczema or respiratory atopy, or hypertrophy of the gums, it furthermore being possible for the compounds to be used for some. . .

SUMM . . . is known that compositions of this type can be used, for example, for the therapy of psoriasis, various forms of eczema, irritative and toxic dermatitis, UV dermatitis and further allergic and/or inflammatory diseases of the skin and integumentary appendages. Compositions according. . .

CLM What is claimed is:

. . . a defect of keratinisation, ichthyosis, an ichthyosiform state, Darier's disease, keratosis palmoplantaris, leukoplasia, a leukoplasiform state, skin and mucosal (buccal) eczema (lichen); for the treatment of a skin disease that is associated with defective keratinisation and has an inflammatory and/or immunoallergic component, or psoriasis relating to the skin, mucous membranes or finger- or toenails, or psoriatic rheumatism or skin atopy, eczema, or respiratory atopy, or hypertrophy of the gums, for the prophylaxis and/or treatment of a benign or malignant excrescence of. . .

CLM What is claimed is:

. . . a defect of keratinisation, ichthyosis, an ichthyosiform state, Darier's disease, keratosis palmoplantaris, leukoplasia, a leukoplasiform state, skin and mucosal (buccal) eczema (lichen); for the treatment of a skin disease that is associated with defective keratinisation and has an inflammatory and/or immunoallergic component, or psoriasis relating to the skin, mucous membranes or finger- or toenails, or psoriatic rheumatism or skin atopy, eczema, or respiratory atopy, or hypertrophy of the gums.

IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 58-95-7,

Tocopherol acetate 59-67-6, Nicotinic acid, biological studies
 79-83-4, Pantothenic acid 118-56-9, 3,3,5-Trimethylcyclohexylsalicylate
 131-57-7, 2-Hydroxy-4-methoxybenzophenone 1022-78-2 5997-53-5
 6197-30-4, Acrylic acid, 2-cyano-3,3-diphenyl-, 2-ethylhexyl ester
 10020-01-6 10191-41-0, DL- α -Tocopherol 24672-78-4
 27457-25-6D, Pyrimidinecarboxylic acid, derivs. 27503-81-7,
 2-Phenylbenzimidazole-5-sulfonic acid 36861-47-9,
 3-(4-Methylbenzylidene)-dl-camphor 42059-55-2 58817-05-3
 63250-25-9, 4-Isopropylidibenzoylmethane 70356-09-1,
 1-(4-Methoxyphenyl)-3-(4-tert-butylphenyl)propane-1,3-dione
 96702-03-3, Ectoin 150668-35-2 158099-19-5 841277-59-6
 (synthesis and use of chromene-4-one derivs. for care of skin and hair)

L10 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2004:133909 USPATFULL
 TITLE: Tricyclic quinoxaline derivatives as a uv filter
 INVENTOR(S): Pflucker, Frank, Darmstadt, GERMANY, FEDERAL REPUBLIC
 OF
 Schwarz, Michael, Weiterstadt, GERMANY, FEDERAL
 REPUBLIC OF
 Scholz, Volker, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
 Neunhofer, Hans, Muhltal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20040102446	A1	20040527	<--
	US 7101537	B2	20060905	
APPLICATION INFO.:	US 2003-471101	A1	20030908	(10)
	WO 2002-EP1402		20020211	

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-10111728	20010309
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Millen White, Zelano & Branigan, Arlington Courthouse Plaza I, 2200 Clarendon Boulevard Suite 1400, Arlington, VA, 22201	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2112	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of quinoxaline derivatives of formula
 I, represented by formulas 1a and 1b, as photostable UV filters, in
 particular in cosmetic and pharmaceutical preparations for protecting
 the human epidermis or human hair against UV radiation, above all in the
 280-400 nm range. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . is known that preparations of this type can be used, for
 example, for the therapy of psoriasis, various forms of eczema
 , irritative and toxic dermatitis, UV dermatitis and further allergic
 and/or inflammatory diseases of the skin and integumentary appendages.
 Preparations according. . .

IT 50652-76-1, 2-Hydroxy-5-methylaurophenone oxime 96702-03-3,
 Ectoin 165542-15-4, Hydroxyectoin 457899-12-6
 (antioxidants stabilized by; preparation of quinoxaline derivs. for use as
 as UV filter stabilizers in cosmetic and pharmaceutical formulations)

L10 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2004:63310 USPATFULL

TITLE: Ectoin or ection derivatives and surfactants
 INVENTOR(S): Buenger, Joachim, Oetzberg-Hering, GERMANY, FEDERAL
 REPUBLIC OF
 Driller, Hans-Juergen, Gross-Umstadt, GERMANY, FEDERAL
 REPUBLIC OF
 Martin, Roland, Weinheim, GERMANY, FEDERAL REPUBLIC OF
 PATENT ASSIGNEE(S): Merck Patent GmbH, Darmstadt, GERMANY, FEDERAL REPUBLIC
 OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040047828	A1	20040311 <--
APPLICATION INFO.:	US 2003-620812	A1	20030717 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-744945, filed on 31 Jan 2001, GRANTED, Pat. No. US 6602514 A 371 of International Ser. No. WO 1999-EP5239, filed on 22 Jul 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19834817	19980801
	DE 1999-DE19911775	19990317
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	840	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of one or more compounds selected from the compounds of formulas (Ia) and (Ib), to the physiologically compatible salts of compounds of formulas (Ia) and (Ib), and to the stereoisomeric forms of the compounds of formulas (Ia) and (Ib), whereby R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n have the meanings cited in Claim Nr. 1. The compounds are used for producing a cosmetic formulation. The compounds are, for example, advantageously used for protecting cells, proteins and/or biomembranes of the human skin, for protecting the microflora of the human skin, for stabilizing the skin barrier, and/or for ameliorating effects of surfactants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . microorganisms increases in the case of moist skin, for example, as a result of inflammatory changes in the case of eczema, by up to 1000-fold.

IT 107-43-7, Betaine 151-21-3, Sodium dodecyl sulfate, biological studies 541-02-6, Mirasil CM 5 2235-54-3, Ammonium laurylsulfate 3198-32-1D, Benzene sulfonate, alkyl derivs. 9004-82-4, Sodium lauryl ether sulfate 84750-06-1, Arlacel 165 96702-03-3 110734-66-2, AbilWE09 129651-72-5, Luvitol EHO 148093-12-3, Sepigel 305 165542-15-4 , (S,S)-1,4,5,6-Tetrahydro-5-hydroxy-2-methyl-4-pyrimidinecarboxylic acid (cosmetic prepns. containing ectoin or ection derivs. and surfactants)

=> END

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
149.38	164.88

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.38	-7.38

STN INTERNATIONAL LOGOFF AT 20:16:17 ON 05 JUN 2009